StreetInsider.com News Articles

Form 8-K Lucid Diagnostics Inc. For: Oct 12

Fri, 16 Oct 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20261016/27198279.html

Form 8-K Lucid Diagnostics Inc. For: Sep 22

Tue, 22 Sep 2026 09:07:00 -0400

si-local-file:///var/storage/secattach/20260922/27088821.html

Lucid Diagnostics gets coding and billing updates for esophageal tests

Tue, 22 Sep 2026 07:57:04 -0400

Lucid Diagnostics Inc. (Nasdaq: LUCD), a subsidiary of PAVmed Inc. (Nasdaq: PAVM), announced developments across three regulatory and coding proceedings affecting its EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device, according to a company press release.

A Medicare Advisory Panel on Clinical Diagnostic Laboratory Tests, convened by the Centers for Medicare & Medicaid Services (CMS) on September 15-16, recommended maintaining the original gapfill payment basis for EsoGuard under the Clinical Laboratory Fee Schedule, using PLA code 0114U. The payment rate has been in effect since the CY2021 CLFS Update. CMS is expected to issue final determinations in November following

Lucid Diagnostics gets coding and billing updates for esophageal tests

Tue, 22 Sep 2026 07:57:04 -0400

Lucid Diagnostics Advances Multiple EsoGuard® and EsoCheck® Payment, Billing and Coding Pathways

Tue, 22 Sep 2026 07:55:00 -0400

Medicare Advisory Panel recommends maintaining EsoGuard's original gapfill payment basis under the Clinical Laboratory Fee Schedule

AMA CPT Editorial Panel approves a new Category III CPT code for non-endoscopic cell collection procedures performed with EsoCheck

Proposal for a new ICD-10-CM diagnosis code identifying positive EsoGuard results draws a favorable response

Lucid Diagnostics Advances Multiple EsoGuard® and EsoCheck® Payment, Billing and Coding Pathways

Tue, 22 Sep 2026 07:55:00 -0400

Medicare Advisory Panel recommends maintaining EsoGuard's original gapfill payment basis under the Clinical Laboratory Fee Schedule

AMA CPT Editorial Panel approves a new Category III CPT code for non-endoscopic cell collection procedures performed with EsoCheck

Proposal for a new ICD-10-CM diagnosis code identifying positive EsoGuard results draws a favorable response

Lucid Diagnostics Advances Multiple EsoGuard® and EsoCheck® Payment, Billing and Coding Pathways

Tue, 22 Sep 2026 07:55:00 -0400

Medicare Advisory Panel recommends maintaining EsoGuard's original gapfill payment basis under the Clinical Laboratory Fee Schedule

AMA CPT Editorial Panel approves a new Category III CPT code for non-endoscopic cell collection procedures performed with EsoCheck

Proposal for a new ICD-10-CM diagnosis code identifying positive EsoGuard results draws a favorable response

Lucid Diagnostics Advances Multiple EsoGuard® and EsoCheck® Payment, Billing and Coding Pathways

Tue, 22 Sep 2026 07:55:00 -0400

Medicare Advisory Panel recommends maintaining EsoGuard's original gapfill payment basis under the Clinical Laboratory Fee Schedule

AMA CPT Editorial Panel approves a new Category III CPT code for non-endoscopic cell collection procedures performed with EsoCheck

Proposal for a new ICD-10-CM diagnosis code identifying positive EsoGuard results draws a favorable response

PAVmed Provides Business Update and Reports Second Quarter 2026 Financial Results

Fri, 14 Aug 2026 08:00:00 -0400

Veris Health accelerated its commercial engagement with OSU-The James
Veris Health implantable physiological monitor achieved development milestones towards upcoming FDA submission
Lucid Diagnostics secured first laboratory benefit manager coverage policy for EsoGuard ^®
Conference call and webcast to be held today, August 14, at 8:30 AM EDT
NEW YORK, Aug. 14, 2026 /PRNewswire/ -- PAVmed Inc. (NASDAQ: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors, today provided a business

PAVmed Provides Business Update and Reports Second Quarter 2026 Financial Results

Fri, 14 Aug 2026 08:00:00 -0400

Veris Health accelerated its commercial engagement with OSU-The James
Veris Health implantable physiological monitor achieved development milestones towards upcoming FDA submission
Lucid Diagnostics secured first laboratory benefit manager coverage policy for EsoGuard ^®
Conference call and webcast to be held today, August 14, at 8:30 AM EDT
NEW YORK, Aug. 14, 2026 /PRNewswire/ -- PAVmed Inc. (NASDAQ: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors, today provided a business

PAVmed Provides Business Update and Reports Second Quarter 2026 Financial Results

Fri, 14 Aug 2026 08:00:00 -0400

Veris Health accelerated its commercial engagement with OSU-The James
Veris Health implantable physiological monitor achieved development milestones towards upcoming FDA submission
Lucid Diagnostics secured first laboratory benefit manager coverage policy for EsoGuard ^®
Conference call and webcast to be held today, August 14, at 8:30 AM EDT
NEW YORK, Aug. 14, 2026 /PRNewswire/ -- PAVmed Inc. (NASDAQ: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors, today provided a business

PAVmed Provides Business Update and Reports Second Quarter 2026 Financial Results

Fri, 14 Aug 2026 08:00:00 -0400

Veris Health accelerated its commercial engagement with OSU-The James
Veris Health implantable physiological monitor achieved development milestones towards upcoming FDA submission
Lucid Diagnostics secured first laboratory benefit manager coverage policy for EsoGuard ^®
Conference call and webcast to be held today, August 14, at 8:30 AM EDT
NEW YORK, Aug. 14, 2026 /PRNewswire/ -- PAVmed Inc. (NASDAQ: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors, today provided a business

PAVmed Provides Business Update and Reports Second Quarter 2026 Financial Results

Fri, 14 Aug 2026 08:00:00 -0400

Veris Health accelerated its commercial engagement with OSU-The James
Veris Health implantable physiological monitor achieved development milestones towards upcoming FDA submission
Lucid Diagnostics secured first laboratory benefit manager coverage policy for EsoGuard ^®
Conference call and webcast to be held today, August 14, at 8:30 AM EDT
NEW YORK, Aug. 14, 2026 /PRNewswire/ -- PAVmed Inc. (NASDAQ: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors, today provided a business

PAVmed Provides Business Update and Reports Second Quarter 2026 Financial Results

Fri, 14 Aug 2026 08:00:00 -0400

Veris Health accelerated its commercial engagement with OSU-The James
Veris Health implantable physiological monitor achieved development milestones towards upcoming FDA submission
Lucid Diagnostics secured first laboratory benefit manager coverage policy for EsoGuard ^®
Conference call and webcast to be held today, August 14, at 8:30 AM EDT
NEW YORK, Aug. 14, 2026 /PRNewswire/ -- PAVmed Inc. (NASDAQ: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors, today provided a business

PAVmed Provides Business Update and Reports Second Quarter 2026 Financial Results

Fri, 14 Aug 2026 08:00:00 -0400

Veris Health accelerated its commercial engagement with OSU-The James
Veris Health implantable physiological monitor achieved development milestones towards upcoming FDA submission
Lucid Diagnostics secured first laboratory benefit manager coverage policy for EsoGuard ^®
Conference call and webcast to be held today, August 14, at 8:30 AM EDT
NEW YORK, Aug. 14, 2026 /PRNewswire/ -- PAVmed Inc. (NASDAQ: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors, today provided a business

PAVmed Provides Business Update and Reports Second Quarter 2026 Financial Results

Fri, 14 Aug 2026 08:00:00 -0400

Veris Health accelerated its commercial engagement with OSU-The James
Veris Health implantable physiological monitor achieved development milestones towards upcoming FDA submission
Lucid Diagnostics secured first laboratory benefit manager coverage policy for EsoGuard ^®
Conference call and webcast to be held today, August 14, at 8:30 AM EDT
NEW YORK, Aug. 14, 2026 /PRNewswire/ -- PAVmed Inc. (NASDAQ: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors, today provided a business

PAVmed Provides Business Update and Reports Second Quarter 2026 Financial Results

Fri, 14 Aug 2026 08:00:00 -0400

Veris Health accelerated its commercial engagement with OSU-The James
Veris Health implantable physiological monitor achieved development milestones towards upcoming FDA submission
Lucid Diagnostics secured first laboratory benefit manager coverage policy for EsoGuard ^®
Conference call and webcast to be held today, August 14, at 8:30 AM EDT
NEW YORK, Aug. 14, 2026 /PRNewswire/ -- PAVmed Inc. (NASDAQ: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors, today provided a business

PAVmed Provides Business Update and Reports Second Quarter 2026 Financial Results

Fri, 14 Aug 2026 08:00:00 -0400

Veris Health accelerated its commercial engagement with OSU-The James
Veris Health implantable physiological monitor achieved development milestones towards upcoming FDA submission
Lucid Diagnostics secured first laboratory benefit manager coverage policy for EsoGuard ^®
Conference call and webcast to be held today, August 14, at 8:30 AM EDT
NEW YORK, Aug. 14, 2026 /PRNewswire/ -- PAVmed Inc. (NASDAQ: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors, today provided a business

PAVmed Provides Business Update and Reports Second Quarter 2026 Financial Results

Fri, 14 Aug 2026 08:00:00 -0400

Veris Health accelerated its commercial engagement with OSU-The James
Veris Health implantable physiological monitor achieved development milestones towards upcoming FDA submission
Lucid Diagnostics secured first laboratory benefit manager coverage policy for EsoGuard ^®
Conference call and webcast to be held today, August 14, at 8:30 AM EDT
NEW YORK, Aug. 14, 2026 /PRNewswire/ -- PAVmed Inc. (NASDAQ: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors, today provided a business

PAVmed Provides Business Update and Reports Second Quarter 2026 Financial Results

Fri, 14 Aug 2026 08:00:00 -0400

Veris Health accelerated its commercial engagement with OSU-The James
Veris Health implantable physiological monitor achieved development milestones towards upcoming FDA submission
Lucid Diagnostics secured first laboratory benefit manager coverage policy for EsoGuard ^®
Conference call and webcast to be held today, August 14, at 8:30 AM EDT
NEW YORK, Aug. 14, 2026 /PRNewswire/ -- PAVmed Inc. (NASDAQ: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors, today provided a business

Needham Reiterates Buy Rating on Lucid Diagnostics Inc (LUCD)

Thu, 13 Aug 2026 11:11:25 -0400

Needham analyst Mike Matson reiterated a Buy rating and $3.00 price target on Lucid Diagnostics Inc (NASDAQ: LUCD).
The analyst commented: "In 2Q26, EsoGuard test volume grew 1% Y/Y to 2,770. LUCD's 2Q26 revenue came in above consensus and its operating expenses were below our estimate. LUCD ended 2Q26 with ~$33M of cash as its cash burn decreased moderately from 1Q26. Given LUCD's published data and positive Contractor Advisory Committee (CAC) Meeting on 9/4/25, we think it's very likely that CMS will issue a draft Local Coverage Determination (LCD) covering EsoGuard this year. We expect LUCD's revenue growth to increase and

Form 8-K Lucid Diagnostics Inc. For: Aug 13

Thu, 13 Aug 2026 08:23:00 -0400
si-local-file:///var/storage/secattach/20260813/26917011.html

Form 8-K Lucid Diagnostics Inc. For: Aug 13

Thu, 13 Aug 2026 08:23:00 -0400
si-local-file:///var/storage/secattach/20260813/26917011.html

Lucid Diagnostics Inc. (LUCD) Reports In-Line Q2 EPS

Thu, 13 Aug 2026 08:07:04 -0400

Lucid Diagnostics Inc. (NASDAQ: LUCD) reported Q2 EPS of ($0.06), in-line with the analyst estimate of ($0.06). Revenue for the quarter came in at $1.47 million versus the consensus estimate of $1.43 million.
For earnings history and earnings-related data on Lucid Diagnostics Inc. (LUCD) click here.

Lucid Diagnostics Provides Business Update and Reports Second Quarter 2026 Financial Results

Thu, 13 Aug 2026 08:00:00 -0400

Recognized 2Q26 revenue of $1.5 million
Processed 2,770 EsoGuard ^® tests
Secured first laboratory benefit manager (LBM) EsoGuard coverage policy
Conference call and webcast to be held today, August 13, at 8:30 AM EDT
NEW YORK, Aug. 13, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM) ("PAVmed"), today provided a business update for the Company and reported financial results for the second quarter